Pregled bibliografske jedinice broj: 1100723
Mid1 is a novel mediator of subchondral bone resorption in antigen-induced arthritis
Mid1 is a novel mediator of subchondral bone resorption in antigen-induced arthritis // Abstracts of the ECTS Congress 2019 / Teti, A (ur.).
Budimpešta, Mađarska, 2019. str. 39-40 doi:10.1007/s00223-019-00541-0 (predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1100723 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Mid1 is a novel mediator of subchondral bone
resorption in antigen-induced arthritis
Autori
Lukač, Nina ; Šućur, Alan ; Flegar, Darja ; Kelava, Tomislav ; Zrinski Petrović, Katerina ; Šisl, Dino ; Katavić, Vedran ; Grčević, Danka ; Kovačić, Nataša.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the ECTS Congress 2019
/ Teti, A - , 2019, 39-40
Skup
46th European Calcified Tissue Society Congress
Mjesto i datum
Budimpešta, Mađarska, 11.05.2109. - 14.05.2109
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Mid1, Bone resorption, Arthritis
Sažetak
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune joint disease characterized by subchondral bone destruction not reversible by currently available therapeutics. We have shown that mice deficient for Fas gene (Fas-/-) are protected from local bone resorption in antigen-induced arthritis (AIA), a murine model of RA, and have a lower frequency of synovial myeloid cells, which downregulate Mid1 gene. The objective of the study was to evaluate the role of Mid1 in bone resorption in AIA. Materials and methods: After receiving ethical approval, arthritis was induced by immunization of mice with methylated bovine serum albumin (mBSA) with subsequent intra articular injection of mBSA. Synovial myeloid (CD11b + Gr- 1 +) cell transcriptome was analyzed by Affymetrix ST 2.0 arrays. Bioinformatics analysis was performed using Bioconductor. Differences in gene expression were confirmed by qRT-PCR. WT-AIA mice were treated in vivo with metformin, which inhibits proinflammatory effect of Mid1, at daily dose 1 g/kg, to assess effects on arthritis development. Results: Mid1 gene was up-regulated in myeloid cells (logFC = 2.01, p(BH-adjusted) = 0.0003, limma BH-adjustment) and bulk joint tissue (logFC = 8.74, p = 0.02, Welch-test) of WT mice in comparison to Fas-/- mice with non-resorptive arthritis. Despite its position on X chromosome Mid1 expression in joints was not sexually dimorphic and was up-regulated in WT- AIA in both male (logFC = 1.92, p = 0.006, T-test) and female mice (logFC = 8.74, p = 0.02, Welch-test). Furthermore, expression positively correlated with knee diameter (r = 0.68, p = 0.03, Spearman's rank correlation) and levels of pro-inflammatory cytokines in arthritis joints (IL-1: r = 0.78, p = 0.008 ; IL-6: r = 0.70, p = 0.025 ; TNF:r = 78, p = 0.008, Spearman's rank correlation). Metformin treatment of WT-AIA mice ameliorated the severity of arthritis assessed by knee diameter (3.69 ± 0.21 mm WT-AIA vs. 3.36 ± 0.12 mm WT-AIA ? metformin, p = 0.008, T-test). Conclusions: Mid1 is a novel mediator of subchondral bone destruction in arthritis and its inhibition might present a new therapeutic target for inflammation-mediated joint destruction.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
--IP-2014-09-7406 - Molekularni posrednici koštane resorpcije uvjetovane receptorom Fas u artritisu (MEFRA) (Kovačić, Nataša) ( CroRIS)
IP-2013-11-5699 - Karakterizacija reakcije osteoklastnih progenitora na artritis (COPERA) (Grčević, Danka, HRZZ - 2013-11) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Danka Grčević
(autor)
Alan Šućur
(autor)
Dino Šisl
(autor)
Tomislav Kelava
(autor)
Nataša Kovačić
(autor)
Darja Flegar
(autor)
Vedran Katavić
(autor)
Nina Lukač
(autor)